Business UpdateMay 26, 2026, 07:02 AM
Tonix Presents Real-World Fibromyalgia Data at ISPOR 2026
AI Summary
Tonix Pharmaceuticals presented data from a real-world claims analysis characterizing U.S. adults with fibromyalgia at ISPOR 2026. The study, covering over 261,000 patients in 2023-2024, highlighted a high comorbidity burden, multimodal treatment approaches, and extensive healthcare resource utilization (HCRU) among fibromyalgia patients. These findings underscore the significant unmet need that Tonix aims to address with TONMYA, which commercially launched in November 2025 as the first new fibromyalgia drug approved in over 15 years.
Key Highlights
- Tonix presented real-world claims analysis data from over 261,000 U.S. adults with fibromyalgia.
- 93.2% of patients had at least one fibromyalgia-related comorbidity.
- Anxiety/depression was the most common comorbidity at 63.9%.
- Inpatient services represented the largest HCRU component at $29,896 per patient annually.
- Pharmacy costs were $9,453 and outpatient costs were $6,196 per patient annually.
- Antidepressants were the most frequently used medication class at 48.2%.
- TONMYA was approved by the FDA on August 15, 2025, and launched in November 2025.
- TONMYA patents are expected to provide U.S. market exclusivity until 2034/2035.
Price Impact
More from TNXP